Product Description
Mechanisms of Action: DPP4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Argentina | India | Italy | Japan | Korea | Philippines
Approved Indications: None
Known Adverse Events: None
Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description

Countries in Clinic: Korea
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Type 2 Diabetes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
---|---|---|---|---|---|---|---|
TERA 304 | P3 |
Completed |
Type 2 Diabetes |
2024-04-23 |
52% |
2025-01-25 |
|
TERA 305 | P3 |
Completed |
Type 2 Diabetes |
2023-11-30 |
52% |
2025-01-28 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Start Date|Study Completion Date|Treatments|Trial Status |